Recent Patents on Cardiovascular Drug Discovery


Novel Antidepressant Drugs, Arterial Hypertension and Cardiovascular Disease

Author(s): Vasiliki K. Katsi, Maria Marketou, Georgia Vamvakou, Thomas Makris, Dimitris Tousoulis, Christodoulos I. Stefanadis, Panos Vardas and Ioannis E. Kallikazaros

Affiliation: Cardiology Department, Hippokration Hospital, Greece, Vas. Sofias Avenue 114, Post code: 11527, Athens, Greece.

Keywords: Arterial hypertension, bupropion, cardiovascular disease, depression, fluoxetine, norepinephrine reuptake inhibitors, serotonin reuptake inhibitors.


Depression is a common mental health issue worldwide leading to disability, functional decline and increased mortality. Novel antidepressants have been developed during the last decades in order to treat depression syndromes. Some evidence suggests that major depression has been associated with the development of congestive heart failure and with adverse outcomes in patients with coronary heart disease. The purpose of the present article is to review the impact of novel antidepressant patent drugs on cardiovascular disease and arterial hypertension.

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [178 - 185]
Pages: 8
DOI: 10.2174/1574890109666140407154738